ClinicalTrials.gg
Active, not recruitingNCT05866432TUXEDO-2Updated Oct 30, 2026

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

A Phase 2 interventional study of Datopotamab deruxtecan in Breast Cancer Stage IV, sponsored by Medical University of Vienna. Active, not recruiting at 1 site in Austria. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Medical University of Vienna · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 30, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Planned enrollment
14th of 14
20 · median 300
Started
2023
with 2 others
Phase 2
6 of 14
5 open now
Primary completion
2026-07
later than 4 of 13 live
Registered
6th of 14
by date
Lead sponsor
1 of 14
Medical University of Vienna

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 14th largest by planned enrollment, is one of 3 that started in 2023, is one of 6 in phase 2, reaches primary completion later than 4 of the 13 other live ones, and was the 6th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.

Read the detailed description

Datopotamab-deruxtecan will be administered at a dose of 6.0 mg/kg body weight i.v. on day

1 once every three weeks in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases. Response rate by RANO-BM criteria is definied as primary endpoint.

03

Conditions studied

  • Breast Cancer Stage IV

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed breast cancer
  • Triple-negative disease as defined by immunohistochemistry (IHC) and/or c-erb-B2 gene amplification status. For the definition of hormone-receptor negative disease, a cut-off of \<10% tumour cells with positive staining of oestrogen- and progresteron-receptors is required
  • Newly diagnosed untreated or brain metastases progressing after prior local therapy
  • (RANO-BM criteria)
  • No indication for immediate local treatment
  • Accompanying type II allowed (suspected LMD by clinical findings and neuroimaging)
  • ≥70%, ≤2 Indication for systemic anti-cancer treatment
  • Prior exposure to , PD-L1 inhibitors and TROP-2 targeted agents allowed
  • of at least 3 months
  • Age ≥18 years
  • Patient must be able to tolerate therapy
  • Adequate bone-marrow, liver and kidney function
  • Adequate treatment before enrolment, defined as:
  • Major Surgery: ≥3 weeks
  • Radiation therapy to the chest: ≥4 weeks
  • Palliative radiation therapy to other areas: ≥2 weeks
  • Chemotherapy, small-molecule targeted agents: ≥3 weeks
  • Antibody-based treatment: ≥4 weeks (concurrent therapy with denosumab allowed)
  • Patient must be capable of understanding the purpose of the study and have given written

Exclusion criteria

Exclusion Criteria:

  • Known to Dato-DXd or any of the drug components
  • Use of any agent within 28 days prior to initiation of treatment
  • History of other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 3 years including contralateral breast cancer
  • Other anticancer therapy, including cytotoxic, targeted agents, immunotherapy, antibody, retinoid, or anti-cancer hormonal treatment with the exception of osteoprotective therapies such as denosumab or bisphosphonates
  • Concomitant radiotherapy
  • A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be and adversely affecting compliance to study drugs
  • Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure ( III-IV), \<50%, arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities, and long syndrome (QTc interval >470 ms)
  • Inadequate bone marrow function at baseline prior to study entry
  • Inadequate kidney function
  • Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver or stable chronic liver disease including active or uncontrolled infections with and C
  • Participants with known hepatitis B and C are eligible if they:

    1. Have been curatively treated for infection as demonstrated clinically and by viral serologies
    2. Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis
    3. Are HBsAg- and anti-HBc+ (i.e., those who have cleared HBV after infection) and meet conditions i-iii below:
    4. Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions 1-3 below:
    5. HBV DNA viral load \<2000 IU/mL
    6. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of /ALT \<3 × , which are not attributable to HBV infection
    7. Start or maintain antiviral treatment
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Has a history of non-infectious ILD/pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Subjects with bronchopulmonary disorders who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study
  • Patients with active opportunistic infections
  • Known (HIV) infection that is not well controlled
  • Pregnant or lactating women
  • Women with , including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate from study start to one year after the last dose of protocol therapy.
  • Male subjects unable or unwilling to use adequate contraception methods
  • Patients with known substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results
  • Patients requiring concomitant use of chronic systemic (IV or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other medications except for managing adverse events; (inhaled steroids or intra articular steroid injections are permitted in this study)
  • Patients with significant corneal disease
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Datopotamab-deruxtecan

    Datopotamab-deruxtecan (DS-1062a) 6.0 mg/kg body weight i.v. on day 1 once every three weeks

    Drug: Datopotamab deruxtecan

Interventions

06

What researchers measure

Primary outcomes

  1. Intracranial response rate to datopotamab-deruxtecan

    Measured according to RANO-BM criteria

    Time frame: From date of inclusion until the date of firstdocumented progression or date of death from any cause or treatmentdiscontinuation from any other reason, whichever came first, assessedup to 36 months]

Secondary outcomes

  1. Entracranial response rate to datopotamab-deruxtecan

    Measured according to RECIST 14.1 criteria

    Time frame: From date of inclusion until the date of firstdocumented progression or date of death from any cause or treatmentdiscontinuation from any other reason, whichever came first, assessedup to 36 months]

  2. Progression-free survival

    Time from inclusion until progression

    Time frame: From date of inclusion until the date of firstdocumented progression or date of death from any cause or treatmentdiscontinuation from any other reason, whichever came first, assessedup to 36 months]

  3. Overall Survival

    Time from inclusion until progression

    Time frame: From date of inclusion until the date of firstdocumented progression or date of death from any cause or treatmentdiscontinuation from any other reason, whichever came first, assessedup to 36 months]

  4. Safety & tolerability of datopotamab-deruxtecan in terms of haematologic and non-haematologic side effect

    Assessment of clinical adverse events \& laboratory parameters

    Time frame: From date of inclusion until the date of firstdocumented progression or date of death from any cause or treatmentdiscontinuation from any other reason, whichever came first, assessedup to 36 months]

07

Study locations

1 site
  • AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology
    Vienna, 1090, Austria
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2026, 36 months.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 36 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion May 2026 → Jul 2026 and completion May 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 19, 2023
StartActual
Jul 1, 2023
Primary completionActual
Jul 1, 2026was May 2026
CompletionEst.
Jul 1, 2027was May 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology · Vienna, Austria
Show 1 removed
  • AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology · Vienna, Austria
Oct 30, 2026
Primary completion
May 23, 2026→Jul 1, 2026 (actual)
Oct 30, 2026
Study completion
May 23, 2026→Jul 1, 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology · Vienna, Austria
    Show 1 removed
    • AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology · Vienna, Austria
    Primary completion May 23, 2026→Jul 1, 2026 (now actual)
    Study completion May 23, 2026→Jul 1, 2027
    + 4 other changes: verification date, oversight details, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05866432
Collaborators
Daiichi Sankyo
Responsible party
Rupert Bartsch (Assoc.-Prof. PD Dr., Medical University of Vienna) — Principal investigator
First posted
May 19, 2023
Start date
Jul 1, 2023
Primary completion
Jul 1, 2026
Completion
Jul 1, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Rupert Rupert, MD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion